#VisualAbstract: Obicetrapib Reduced LDL Cholesterol in Patients at High Cardiovascular Risk
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: LDL cholesterol
Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
1. ANGPTL4 inhibition decreased triglyceride and remnant cholesterol levels by over 50%. 2. MAR001 was well-tolerated with no significant treatment-related ...
Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients
1. FDC obicetrapib plus ezetimibe significantly decreased LDL cholesterol levels by 48.6% compared to placebo. 2. Serious adverse events were ...
#VisualAbstract: Roux-en-Y gastric bypass is superior to laparoscopic sleeve gastrectomy to reduce short-term LDL cholesterol
Click here to read this study in BMC. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Urgent need for improved detection of pediatric familial hypercholesterolemia worldwide
1. 92.4% of children in high-income countries had heterozygous familial hypercholesterolemia compared to 48.0% in non-high-income countries. 2. The majority ...
C-reactive protein may have superior prognostic value compared to low-density lipoprotein cholesterol for patients on statin therapy
1. High-sensitivity C-reactive protein increased the risk of all-cause mortality by two- to three-fold among all three randomized trials. 2. ...
Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease
1. In this genetic association study, among 209 537 participants, a protein-truncating variant (PTV) was identified in 0.4% of individuals, ...
![Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/09/800px-RCA_atherosclerosis-350x250.jpg)
Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease
1. Olpasiran significantly and substantially reduced lipoprotein(a) concentration in patients with atherosclerotic cardiovascular disease compared to placebo. 2. Olpasiran reduced ...
Risk of myopathy and myalgia among statin users may be small and clinically insignificant
1. 27.1% of patient in the statin group reported muscle pain and weakness compared to 26.6% in the control groups. ...
Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy
1. 3-year composite outcome of stroke and cardiovascular disease was comparable between both groups (9.1% combination vs. 9.9% monotherapy). 2. ...
